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Background: Osteoarthritis (OA), the most common form of arthritis, is a major contributor to functional
impairment and loss of independence in older persons. The European Project on OSteoArthritis (EPOSA) is a
collaborative study involving six European cohort studies on ageing. This project focuses on the personal and
societal burden and its determinants of osteoarthritis. This paper describes the design of the project, and presents
some descriptive analyses on selected variables across countries.
Methods/design: EPOSA is an observational study including pre-harmonized data from European cohort studies
(Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom) on older community-dwelling persons
aged 65 to 85 years. In total, 2942 persons were included in the baseline study with a mean age of 74.2 years
(SD 5.1), just over half were women (51,9%). The baseline assessment was conducted by a face-to-face interview
followed by a clinical examination. Measures included physical, cognitive, psychological and social functioning,
lifestyle behaviour, physical environment, wellbeing and care utilisation. The clinical examination included
anthropometry, muscle strength, physical performance and OA exam. A follow-up assessment was performed
12–18 months after baseline.
Discussion: The EPOSA study is the first population-based study including a clinical examination of OA, using pre-
harmonized data across European countries. The EPOSA study provides a unique opportunity to study the
determinants and consequences of OA in general populations of older persons, including both care-seeking and
non care-seeking persons.Background
Osteoarthritis (OA), the most common form of arthritis,
is characterized by focal areas of loss of articular cartil-
age within synovial joints, which are associated with
hypertrophy of bone near the joints (osteophytes and
subchondral bone sclerosis) and thickening of the* Correspondence: s.vanderpas@vumc.nl
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distribution, and reproduction in any mediumcapsule [1]. OA is a major contributor to functional im-
pairment and loss of independence in older persons [2].
The prevalence of OA varies widely and may depend
on OA definition (e.g. self-report versus clinical), site of
interest, study population (patient-based or population-
based) and country [3]. Among persons of 65 years and
older, estimates of the prevalence of OA vary widely. Its
prevalence has been estimated at 9.2% for knee OA and
7.2% for hip OA in the Netherlands [4], 32.6% for knee
pain and 19.2% for hip pain in the United Kingdom [5],
29.8% for knee OA, 7.7% for hip OA, and 14.9% forntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for hand OA in Spain [7]. Recently, efforts to come to a
consensus regarding the diagnosis of OA have lead to
the European League Against Rheumatism (EULAR)
recommendations [8,9]. However, these definitions are
not yet standardized in ongoing cohort studies or in
daily clinical practice.
The European Project on Osteoarthritis (EPOSA)
studies the personal and societal burden and its determi-
nants of OA in the ageing European population using
data from population-based cohort studies across
Europe. These cohorts include not only persons with
severe OA who receive treatment, but also persons with
OA who have not yet sought care and individuals with-
out OA. Emphasis lies on the personal consequences
(such as quality of life and social participation) and soci-
etal consequences (such as health care use) of OA. The
EPOSA project focuses on the most common types of
OA, namely knee, hip and hand OA. Population-based
studies such as this are important as they provide data
on the burden of the disease in terms of prevalence and
impact on quality of life and health status, thus offering
insight into the need for health care and prevention
strategies.
The EPOSA study has been set up in two phases. In
the first phase of EPOSA, post-harmonisation was used
to enable data from existing cohort studies to be com-
bined to explore prevalence rates and consequences of
OA in Europe [10]. Our results showed that there was
little evidence of correspondence of several core data
collection instruments, in particular on the assessment
of OA [10]. These findings reinforced the necessity of
pre-harmonisation procedures in future waves of data
collection in which agreement on used instruments and
measurements is reached before starting a study,
resulting in a pre-harmonized dataset. In the following
phase of EPOSA pre-harmonisation procedures were
used.
This paper aims to present the design of the EPOSA
study, six pre-harmonized European population-based
cohorts on ageing. Also, some descriptive analyses are
presented on selected variables across countries.
Study design and sample characteristics
The EPOSA project involves six cohort studies performed
in six countries: Germany, Italy, the Netherlands, Spain,
Sweden, and United Kingdom. Random samples from
population-based cohorts performed in these countries
are included. Per cohort, sufficient potential participants
were contacted to include approximately 500 participants
per country at baseline. In Italy, a new sample was drawn,
with recruitment procedures and age/sex-distributions
similar to those in the other studies. The age-range is 65–
85 years in all cohorts except for the UK, which has anage-range of 71–79 years. This occurred because the UK
sample was drawn from a birth cohort recruited over a
9-year period. The design and procedures of all six co-
hort studies have been approved by the Ethical Review
Boards of the respective institutions.
Study samples
Germany is represented by the University of Ulm, Insti-
tute of Epidemiology and Medical Biometry and Bethesda
Geriatric Clinic. The study on Activity and Function in
the Elderly in Ulm (ActiFE-Ulm) [11] is embedded in a
European funded study on the prevalence of COPD and
asthma (Indicators for Monitoring COPD and Asthma -
IMCA) at baseline. The primary focus is physical activity
(as measured by sensor technology) and the consequences
of physical activity for cognitive, emotional and social
functioning. Of the 615 randomly selected subjects of the
ActiFE Ulm Study in the defined age range who were
contacted by mail for written consent to participate in the
EPOSA project, a total of 407 individuals agreed corre-
sponding to a response rate of 66.2%. Participants were
living in the greater Ulm, Neu-Ulm and Alb-Donau-Kreis
areas.
Italy is represented by the National Research Council
(CNR), Aging Branch, Institute of Neuroscience, Padova,
and the Department of Medicine, University of Padova.
The sample in Italy includes 468 out of a total of 638
invited independently dwelling subjects with a response
rate of 73.4%. Participants were contacted by a letter
signed also by the Principal Investigator and by their
General Practitioner. Participants were living in a
geographical area of northeastern Italy (Godega di
Sant’Urbano) near the city of Treviso in the Veneto re-
gion, and they were randomly selected from the health
district registries. The registration to receive health care is
mandatory in Italy ensuring the complete coverage of the
population aged 65 and older living in the sampling area.
The Netherlands is represented by the VU University
Medical Center, EMGO Institute for Health and Care
Research, Amsterdam. Data were used from the Longitu-
dinal Aging Study Amsterdam (LASA) [12], an ongoing
cohort study of predictors and consequences of changes
in physical, cognitive, emotional and social functioning
in older persons. For the current study, a total of 698 in-
dividuals were contacted by mail for written consent to
participate in the EPOSA project, of which 574 (82.2%)
agreed. The LASA sample was selected from population
registers in 11 municipalities in the Netherlands and
stratified for age, sex and level of urbanization.
Spain is represented by the Universidad Autónoma de
Madrid Unit of Family Medicine and Primary Care –
Department of Preventive Medicine and Public Health.
The study included is Ageing in Peñagrande [13]. Partic-
ipants were selected from the Register of Health District




Health characteristics Pain, stiffness, physical function (WOMAC/
AUSCAN), chronic conditions, self-reported
OA, joint replacements
Lifestyle characteristics Smoking, alcohol use, physical activity
(LAPAQ)
Social characteristics Lubben Social Network Scale (LSNS),
Maastricht Social Participation Profile
(MSPP), Participation scale (P-scale)
Psychological
characteristics & Wellbeing
Mini-Mental State Exam (MMSE), Hospital
Anxiety Depression Scales (HADS), Pearlin
Mastery Scale, Quality of life (EuroQoL),
self-rated health
Health care utilisation &
physical environment
Health care use and assistance, medication
use, physical environment accessibility and
usability (HACE), weather sensitivity, drive a
car
Clinical exam
Anthropometry Height, weight, waist and calf
circumference
Muscle strength Hand grip strength
Physical performance Walk test, balance test, chair stand test
Musculoskeletal ACR classification criteria for hip, knee and
hand OA
Pain calendar
Pain Joint pain score, pain medication, health
care use
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of the Fuencarral district in Madrid. A total of 708 indi-
viduals were invited to participate, (468 from Aging in
Peñagrande and 240 from a new population sample), of
which 539 (76.1%) agreed. A total of 349 belonged to the
Aging in Peñagrande survivals (2008 wave) [13] and 190
were new individuals elected among population belong-
ing to Peñagrande and Cuatro-Caminos Primary Health
Centers, two Centers of the same Health District Area.
The organization of Spanish Health System with a regis-
ter of all individuals living in the geographical area of
influence of each Primary Health Center ensures that
the sample is population based.
Sweden is represented by the Department of Medical
Epidemiology and Biostatistics at the Karolinska Institute
of Stockholm. The sample was drawn from the Swedish
Twin Register [14]; background information on the partic-
ipants is available through previous contacts by the
Swedish Twin Registry. Of the 916 community dwelling
participants, aged 65 – 85 years, living in Stockholm
County who were invited by letter to participate, a total
of 510 (55.7%) individuals participated.
The United Kingdom is represented by the University
of Southampton, Southampton General Hospital, MRC
Lifecourse Epidemiology Unit. The UK participants were
recruited from the Hertfordshire Cohort Study (HCS), a
population-based sample of men and women born dur-
ing 1931–9 in Hertfordshire, who had previously been
recruited for a study that examined the relationship be-
tween growth in infancy and the subsequent risk of
common adult diseases, including osteoporosis and
osteoarthritis [15]. A total of 592 individuals were in-




The EPOSA data collection is considered a side-study in
all participating cohorts (except in Italy, where a new
sample was drawn). Data collection took place twice
with about 12–18 months between baseline and the
follow-up measurement. Data collection started from
November 2010 to March 2011 in all the countries, and
ended between September and November 2011. Partici-
pants were visited in their homes by trained inter-
viewers, except for Germany, Italy and the Penagrande
cohort in Spain, where participants were examined by a
trained interviewer in a health care center and only dis-
abled persons were visited in their home. The training of
the interviewers took place as follows: a rheumatologist
from the UK center visited each center to train the key
interviewers who were also fluent in English. After the
training, the key interviewer(s) trained other inter-
viewers in their own center. An instruction manual ofthe clinical exam (including protocols for anthropom-
etry, muscle strength, physical performance and osteo-
arthritis exam) was sent to all centers and also a dvd
was made of the clinical OA examination. The duration
of the interview was approximately one and a half hours.
At the end of the interview, six months later, and after
the 1-year follow-up interview, participants were invited
to complete a pain calendar on which they were asked
to score per day the level of joint pain, changes in medi-
cation use, and health care utilisation for the following
two weeks.
Data collection
In the EPOSA study the same measurement instruments
were used in all countries (see Table 1 for study domains
and measurements). Osteoarthritis was assessed by self-
report and a clinical examination of three sites: knees,
hips and hands. Radiographs were obtained of knees and
hips in the UK only.
Measures
Self-reported OA
Self-reported OA was measured by asking participants,
“Do you have OA?”. If participants answered “yes”,
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fingers, hand/wrist, elbows, shoulders, toes, feet, knee,
hip, neck, and back. Self-reported knee, hip or hand OA
was defined as present when the participant reported
having OA in at least one site, knee, hip or hand (fingers
or hand/wrist).
Clinical OA
Algorithms for clinical OA were developed based on the
clinical classification criteria developed by the American
College of Rheumatology (ACR) [16]. Algorithms were
specified both for site specific OA (knee, hip and hand, re-
spectively) and non-specific OA (any of these three joints).
The knee OA clinical diagnosis was based on both history
and physical examination: pain in the knee was evaluated
by the Western Ontario and McMaster Universities OA
Index (WOMAC) pain subscale score [17], plus any 3
of: over 50 years of age, morning stiffness lasting <30
minutes evaluated by the WOMAC stiffness subscale
(score from ‘mild’ to ‘extreme’); crepitus on active mo-
tion in at least one side; bony tenderness in at least one
side; bony enlargement in at least one side, no palpable
warmth of synovium in both knees.
The hip OA clinical diagnosis was based on both his-
tory and physical examination: pain in the hip was evalu-
ated by the WOMAC pain subscale score, plus all of:
pain associated with hip internal rotation in at least one
side; morning stiffness lasting <60 minutes evaluated by
the WOMAC stiffness subscale (score from ‘mild’ to ‘ex-
treme’); and over 50 years of age.
The hand OA clinical diagnosis was based on both his-
tory and physical examination: the pain, aching or stiffness
of the hand was evaluated by the Australian/Canadian OA
Hand Index (AUSCAN) pain and stiffness subscale [18];
plus any 2 of: hard tissue enlargement of 2 or more of the
2nd and 3rd distal interphalangeal (DIPs), 2nd and 3rd
proximal interphalangeal (PIPs), 1st carpometacarpal
(CMC) joints of at least one hand; hard tissue enlargement
of 2 or more DIPs of at least one hand; deformity of at
least 1 of the 2nd and 3rd DIPs, 2nd and 3rd PIPs, 1st
CMC joints of at least one hand. Swelling of the
metacarpophalangeal (MCP) joints which is also included
in the ACR classification criteria as a control to exclude
rheumatic arthritis was only measured in the UK and
Germany.
The WOMAC and AUSCAN are often used as indica-
tors of pain or stiffness in the ACR classification criteria
of OA [19]. The WOMAC pain subscale contains five
items with regard to pain in the knee or hip: during
walking on a flat surface, descending or ascending stairs,
at night in bed, when sitting or lying, when standing.
The AUSCAN pain subscale contains five items relating
to pain experienced performing certain hand functions
(at rest, gripping, lifting, turning, and squeezing objects).Both the WOMAC and AUSCAN ask about pain experi-
enced in the past 48 hours. The WOMAC and AUSCAN
responses to the five items on pain are scaled on a five
point Likert scale ranging from none (0) to extreme pain
(4). For both the WOMAC and AUSCAN missing values
were imputed according to the user manual [17,18]. The
scores were summed to get an overall pain score (range
0–20), and pain was defined by a score of 3 or more
[20], also allowing inclusion of people with mild
symptoms.
Radiographic OA
Hip x-rays consisted of a standard AP pelvis view. Knees
were imaged with AP and lateral radiographs. The former
were weight bearing with the patella positioned centrally
and the latter were standing or supine with attendant knee
flexion. From the total of 444 UK participants, 402 had
knee radiographs and 394 hip radiographs. Joints were not
imaged if they had previously been replaced. Grading of
radiographs was performed by two investigators inde-
pendently, based on scoring system according to Kellgren-
Lawrence.
Joint replacements
The presence of joint replacements was assessed by ask-
ing participants if they had ever had joint replacement
surgery. If participants answered “yes”, location of the
joint replacement, year of joint replacement, and reason
of joint replacement was elicited.
Demographics
Demographic data were collected on age, gender, educa-
tion level and marital status. Education was measured by
the highest level of education completed and categorized
into “elementary school not completed”, “elementary
school completed”, “vocational education/general sec-
ondary education”, and “college or university education”.
Marital status was assessed by asking whether the par-
ticipants were single or never been married, married or
cohabitating, divorced, widowed, registered partnership,
or living apart.
Health characteristics
The WOMAC and AUSCAN Indices are tri-dimensional
disease specific measures that assess the dimensions of
pain, stiffness and physical function [17,18]. The WOMAC
Index consists of 24 questions (5 pain, 2 stiffness, 17 phys-
ical function) and the AUSCAN Index consists of 15 ques-
tions (5 pain, 1 stiffness, 9 physical function). A description
of the WOMAC and AUSCAN pain subscale is given
above (see paragraph on clinical OA). The WOMAC stiff-
ness subscale contains two items regarding stiffness in the
knee or hip: after first awakening in the morning, and after
sitting, lying or resting later in the day. The AUSCAN
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perienced with certain hand functions (after first awaken-
ing in the morning). Both the WOMAC and AUSCAN ask
about stiffness experienced in the past 48 hours. The
WOMAC and AUSCAN responses to the five items on
stiffness are scaled on a five point Likert scale ranging from
none (0) to extreme stiffness (4).
The WOMAC physical function subscale contains
seventeen items relating to difficulty with knee and/or
hip function experienced in the previous 48 hours. The
AUSCAN physical function subscale contains nine items
relating to difficulty with hand function experienced in
the previous 48 hours. The WOMAC and AUSCAN
responses were scaled on a five point Likert scale
ranging from none (0) to extreme difficulty (4). For both
the WOMAC and AUSCAN missing values were
imputed according to the user manual [17,18]. For each
WOMAC and AUSCAN dimension, subscale scores
were normalized resulting in WOMAC and AUSCAN
subscale scores, each ranging from 0 to 100, in which
the three subscales are equally weighted [17,18].
Number of chronic conditions was measured through
self-reported presence of the following chronic diseases
or symptoms that lasted for at least three months or dis-
eases for which the participant had been treated or
followed by a physician: chronic non-specific lung dis-
ease, cardiovascular diseases, peripheral artery diseases,
stroke, diabetes, cancer, and osteoporosis. If participants
answered “yes” then they were asked to specify which
diseases or type. Chronic conditions were evaluated as
the number of diseases and multimorbidity was defined
as the occurrence of 2 or more coexisting conditions.
Lifestyle characteristics
Lifestyle characteristics were measured by self-reports
on smoking, alcohol and physical activity. Both current
smoking status (never, former, current smoker) and
smoking history (age when started smoking, age when
stopped smoking) were assessed. Alcohol consumption
was measured by frequency and amount over the past
year. Physical activity was measured using the validated
LASA Physical Activity Questionnaire (LAPAQ) [21]. Fre-
quency and duration of activities over the past 2 weeks
were asked for walking, cycling, gardening, light and heavy
household work and a maximum of two sports. In order
to calculate the daily activity, the frequency and duration
were multiplied and subsequently divided by 14 days. A
total physical activity score was calculated in minutes/day
and kcal/day.
Social characteristics
The social characteristics were assessed using the
Lubben’s Social Network Scale (LSNS), the Maastricht
Social Participation Profile (MSPP), and the Participationscale. The six-item Lubben’s Social Network Scale
(LSNS) was developed specifically for older populations
[22] and assesses family (3 items) and friendship net-
works (3 items). Responses for questions measuring
number of network contacts ranged from 0 (none) to 5
(nine or more). Total subscale scores were calculated
ranging from 0 to 15. The Maastricht Social Participa-
tion Profile (MSPP) [23] measures frequency and diver-
sity of actual social participation, and is based on
definitions of social participation by older people with a
chronic disease themselves. In this study two subscales
of the MSPP were used: consumptive participation, such
as attending an organised activity (6 items) and formal
participation, such as volunteering work (3 items). The
response categories range from 0 (‘not at all’) to 3 (‘more
than twice a week’). A total score was calculated ranging
from 0 to 21. The Participation scale (P-scale) measures
participation restrictions in people with chronic (phys-
ical) impairments or disabilities [24]. Five items were
used (from the total of eighteen items), measuring the
perception of participation in helping others, taking part
in recreational/social activities, being socially active, vis-
iting others in the community, and visiting public places
in the neighbourhood. The scale has a two-tier question
and response format. First, a participant is asked to indi-
cate whether they participate, more often (1), the same
(2) or less often (3) in a particular aspect of participation
compared to their peers. If people participate less often,
they could indicate how great a problem this is to them,
namely, no problem (1), small problem (2), medium
problem (3) or large problem (5). The overall P-score is
derived by summing the individual item scores. A higher
score indicates a higher level of participation restriction.
Psychological characteristics and wellbeing
Cognitive function was measured by administering the
Mini-Mental State Examination (MMSE) including 20
items [25]. A total score of the MMSE was calculated
ranging from 0 to 30, and cognitive impairment was de-
fined by a score of 23 or less [25]. Validated or translated
versions of the MMSE were used in all centers [26-28].
Anxiety and depressive symptoms were evaluated by
the Hospital Anxiety Depression Scales (HADS) [29].
HADS is a self-report questionnaire comprising 14 four-
point Likert-scaled items, 7 for anxiety (HADS-A) and 7
for depression (HADS-D). The HADS measures levels of
symptoms in the last week. HADS-A and HADS-D were
used as categorical variables with cut-off level of 8 or
more (range of 0 – 21) for presence of depression or
anxiety.
Mastery was measured by means of the 7-item Pearlin
Mastery Scale [30]. The questionnaire consists of seven
statements such as “I have little control over the things
that happen to me.” Response categories range from 1 =
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items range from 7 to 35, but for ease of interpretation 7
is subtracted, so the final scale ranges from 0 to 28, with
higher scores indicating more mastery.
Wellbeing was evaluated by the EuroQoL and self-
rated health. The EuroQoL (EQ-5D) consists of five
questions, each representing one domain: mobility, self-
care, usual activities, pain/discomfort, anxiety/depression
[31]. The answer options differ between the questions,
but can roughly be divided into: no problems, some
problems, extreme problems. In addition, the partici-
pants were asked to assess their own health state on a
visual analogue scale (EQ VAS). Self-rated health (SRH)
was measured with the question: how is your health in
general? [32]. Response categories are ‘very good’, ‘good’,
‘fair’, ‘bad’, or ‘very bad’.
Health care utilisation and physical environment
For health care utilisation, four types of health care ser-
vices were assessed: hospitalization, primary care use,
specialist services use and medication use. For
hospitalization, this involved whether and how many
times the participant had been hospitalized in the last
year (no/yes). For primary care use, the number of visits
to the general practitioner or nurse or visits received at
home by these professionals during last month was
assessed. Specialist care use was assessed by the number
of visits in the last year to the rheumatologist,
traumatologist, orthopaedic surgeon, physiotherapist,
and podiatrist. Medication use was measured by asking
participant which medication, prescribed by a doctor,
they used during the past two weeks. The following in-
formation was asked: the brand name of the drug, the
dosage (expressed as quantity per tablet or per 100 ml, and
dosage form) and the number of times used per day /week/
as needed.
Home care services (formal and informal) was mea-
sured by asking whether the participant had received
help at home in the last year. If the participant answered
“yes”, questions were asked from whom they received
the help, and the type of help (household or personal
care).
Features of the physical environment were measured
using the Home and Community Environment (HACE)
instrument [33] and weather sensitivity. The HACE is a
standardized, self-report instrument designed to assess
barriers and facilitators in several environmental do-
mains [33]. The following features of the neighbourhood
environment from the HACE were examined: parks and
walking areas that are easy to use; places to sit and rest
at bus stops, in parks, or other places where people walk;
and public transportation close to home. A question was
also included on public facilities such as a daily super-
market, bus stop, post office, bank or community centre.Response categories were ‘a lot’, ‘some’, and ‘not at all’.
When participants answered ‘a lot’ or ‘some’, they were
asked whether they made use of the resources. Weather
sensitivity was measured with the question: which wea-
ther condition(s) affects your pain the most? Multiple
response categories are damp/rainy, cold, hot, or no par-
ticular weather condition. In addition, participants were
asked if they drive a car.
Clinical exam
Anthropometry
Height was measured to the nearest 0.001 m using a
stadiometer. Weight was measured to the nearest 0.1 kg
using a calibrated scale. Body Mass Index (BMI) was cal-
culated as weight in kilograms divided by height in
squared meters. Obesity was defined as present by a
BMI of 30 kg/m2 or higher. The waist circumference
was measured to the nearest 0.001 m midway between
the lower rib margin and the iliac crest following a nor-
mal expiration. The calf circumference was measured to
the nearest 0.001 m on the left leg with the participant
standing straight, feet 20 cm apart, body weight equally
distributed on both feet and at the level of the widest
circumference of the calf.
Muscle strength
Grip strength was measured with a strain–gauged dyna-
mometer. Participants were asked to perform two max-
imum force trials with each hand. To calculate the total
score, the maximum values of the right and the left hand
were summed, and divided by two. If only one hand
could be used, the maximum value of that hand was
taken.
Physical performance
Physical performance was measured by three individual
performance tests, namely walking speed, repeated chair
stands and standing balance based on the methods de-
scribed by Guralnik et al. [34]. Walking speed was mea-
sured by time taken to walk 3 meters “as fast as possible
but not running”. Chair stands were measured by time
taken to rise five times from a chair in normal tempo,
without using the hands. The standing balance test was
measured by the ability to perform the tandem stand for
10 s (with one foot behind the other and the heel of the
first foot directly touching the toes of the other foot).
The participants’ times for walking speed and repeated
chair stands were divided into country-specific quartiles
(scores 1–4, participants who were unable to perform
these two tests were scored 0). The tandem stand is cat-
egorized into three groups. For comparability with the
other tests, these three groups received the following
scores: unable (<3 seconds = 0), able to hold position for
3 to <10 seconds (2), and able to hold position for 10
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balance) is scored from 0 to 4, with a score of 0
representing inability to carry out the test, and 4 the best
performance. A summary performance score was
obtained by adding the scores of each test, ranging from
0 to 12.
Pain calendar
Joint pain was assessed with a “pain calendar”. After the
baseline interview, six months after the baseline inter-
view and after the 1-year follow-up interview, partici-
pants were asked to complete a two-week calendar. Per
day the participant indicated, with a score of 0 to 10,
how much joint pain they had experienced and if they
had used additional pain medication because of joint
pain. They were contacted by telephone or letter if no
calendar was returned even after a reminder. If the par-
ticipant had joint pain, additional questions were asked
on consultation of a general practitioner, medical spe-
cialist or whether they had surgery.
Statistical analysis
A description of the attrition up to the EPOSA study is
given, based on selected demographic and health charac-
teristics. The EPOSA cohorts are compared with the last
wave from each cohort study in the different countries.
Baseline demographic and health characteristics are
presented using descriptive statistics, frequency distribu-
tions and percentages. Prevalence rates of self-reported
and clinical OA are computed per site and per country,
and joint replacements are presented using percentages.
All results are weighted except the response, age and sex.
Weighting procedure
Sample weights were calculated to adjust for differences
in age and sex distribution across country samples. The
weights were calculated per sex and per five-year age
category, using the following formula:
W ¼ Nexp=Nobs;
with the Nobs being the number of persons in a specific
age/sex category in the cohort, and Nexp being the
number of persons in a specific age/sex category in the
European population [35]. The expected number of per-
sons was derived from the European Standard Popula-
tion in 2010 [36].
Results
Table 2 shows the recruitment and baseline characteris-
tics of the six cohorts that were included in the EPOSA
study. In total 4,040 participants were selected for re-
cruitment, and 2,942 people aged between 65 to 85 yearswere interviewed (response rate = 72.8%). The baseline
pain calendar was returned by 80.8% of the total sample.
A comparison of participants and refusers, and those
unable, was performed for age, gender, educational level,
chronic conditions, MMSE and depressive symptoms
(results not shown). Those who became refusers or un-
able were older in Sweden, Germany and Spain, and in
Sweden and the Netherlands they had a lower education
level. A number of health characteristics show poorer
health for those who became refusers or unable in the
EPOSA study. In Germany and the Netherlands, the re-
fusers or unable had lower MMSE and more depressive
symptoms. In Sweden, those who became refusers or
unable, had more chronic conditions and lower MMSE.
Significant associations were found among all descrip-
tive characteristics and the EPOSA countries. Overall,
the average age of the sample was 74.2 years (SD = 5.1)
and just over half were women (51.9%). The average age
of the cohorts in Sweden and Italy was lower as com-
pared with the other countries. The level of education
was higher in the UK, Sweden and the Netherlands
compared with Italy and Spain. In Sweden and the
Netherlands the percentage married was lower com-
pared with the other countries. With respect to the
health characteristics, the BMI was the highest in Spain
and the lowest in Sweden. In Sweden and the UK the
percentage with 2 or more chronic conditions was the
lowest. The average physical performance score was 8.4
(range 0–12), with the UK having the lowest physical
performance score.
The alcohol consumption was the lowest in Spain
(38.9%), compared to Germany which had the highest
alcohol consumption (90.0%). In the UK only 3.7% of
the participants were current smokers, while Sweden,
the Netherlands and Spain had the highest prevalence of
smokers (10.1%, 10.5% and 9.2% respectively). Italy had
the highest physical activity score compared to the
Netherlands with the lowest.
Overall, the average number of family relations was 9.2
(SD = 3.2), with little difference across countries, ranging
from 9.9 in Italy to 8.6 in Sweden. The average number of
friends was 7.6 (SD = 3.7), ranging from 8.5 in Germany
and the UK to 6.1 in Spain. In Germany the participants
had the highest social participation (M= 7.2) and in Italy
the lowest (M= 4.3).
In general, participants had a high MMSE score
(Median = 28). For the total sample, the level of anxiety
was higher than that of depression (20.7% and 11.9% re-
spectively). Italy had the highest anxiety and depression
levels (53.1% and 20.9% respectively) and Sweden had
the lowest (7.3% and 1.2% respectively). In general, par-
ticipants had a high mastery (M = 19.3).
Table 3 presents the prevalence rates for self-reported
and clinical knee, hip, and hand OA. The prevalence rate
Table 2 Recruitment and demographic, health, lifestyle, social and psychological characteristics by country
(weighted unless otherwise specified) 1
All
countries
Germany Italy Netherlands Spain Sweden UK p-value
Sample size (unweighted)
Invited (n) 4,040 615 638 698 708 789 592
Responded (N) 2,942 407 468 574 539 510 444
Response rate (%) 72.8 66.2 73.4 82.2 76.1 64.6 75.0
Demographic characteristics
Age (mean (SD) range) (unweighted) 74.2 (5.1) 74.4 (5.0) 73.3 (5.2) 75.2 (5.7) 75.0 (5.5) 72.1 (5.0) 75.2 (2.6) <.0001
Age (range in years) (unweighted) 65-85 65-85 65-85 65-85 65-85 65-85 71-80
Sex (female) (n (%)) (unweighted) 1,527 (51.9) 164 (40.3) 249 (53.2) 317 (55.2) 268 (49.7) 306 (60.0) 222 (50.0) <.0001
Married (yes) (n (%)) 1,934 (63.7) 280 (67.4) 345 (72.8) 341 (57.5) 386 (68.8) 267 (51.5) 315 (69.1) <.0001
Education (≥ secondary education) (n (%)) 1,637 (55.0) 202 (50.1) 105 (22.4) 435 (74.5) 149 (27.6) 391 (76,7) 355 (79.1) <.0001
Health characteristics
BMI (Mean (SD) in kg/m2) 27.7 (4.4) 27.4 (4.0) 28.1 (4.6) 27.6 (4.5) 28.6 (4.3) 26.2 (4.0) 28.1 (4.6) <.0001
Chronic diseases (≥2) (n (%)) 791 (26.9) 100 (25.4) 111 (22.7) 195 (33.4) 182 (35.1) 109 (20.6) 94 (20.9) <.0001
Physical performance score (mean (SD)) 8.4 (2.7) 8.4 (2.7) 8.7 (2.2) 8.2 (2.8) 8.4 (2.9) 8.5 (2.4) 7.8 (2.9) <.0001
Lifestyle characteristics
Alcohol consumption (yes) (n (%)) 2224 (74.9) 367 (90.0) 371 (78.1) 462 (80.7) 223 (38.9) 444 (88.8) 357 (79.0) <.0001
Smoking status (n (%)) <.0001
Never 1,410 (49.5) 199 (50.5) 265 (58.5) 196 (36.9) 299 (58.5) 223 (43.2) 228 (52.8)
Current 232 (8.5) 28 (7.0) 33 (8.2) 55 (10.5) 51 (9.2) 48 (10.1) 17 (3.7)
Ex 1,289 (42.0) 180 (42.5) 170 (33.2) 320 (52.5) 189 (32.4) 231 (46.6) 199 (43.5)















Family (mean (SD)) (0–15) 9.2 (3.2) 9.2 (3.2) 9.9 (2.8) 9.6 (3.3) 9.0 (3.2) 8.6 (3.3) 9.0 (3.2) <.0001
Friends (mean (SD)) (0–15) 7.6 (3.7) 8.5 (3.6) 7.1 (4.0) 7.7 (3.6) 6.1 (4.0) 8.3 (3.1) 8.5 (3.3) <.0001
Social participation (0–21) (mean (SD)) 5.4 (3.8) 7.2 (3.8) 4.3 (3.6) 4.9 (3.6) 4.6 (3.4) 5.3 (3.6) 7.2 (4.0) <.0001
Psychological characteristics
MMSE (median[IQR]) 28 [26-29] 29 [28-30] 27 [25-28] 28 [27-29] 28 [26-29] 27 [26-28] 28 [25-29] <.0001
Anxiety (≥8) (n (%)) 568 (20.7) 54 (14.2) 235 (53.1) 88 (16.5) 87 (17.6) 40 (7.3) 64 (16.4) <.0001
Depression (≥8) (n (%)) 332 (11.9) 32 (7.7) 94 (20.9) 70 (12.7) 99 (19.5) 8 (1.2) 29 (7.4) <.0001
Mastery (0–28) (mean (SD)) 19.3 (5.0) 20.5 (4.1) 16.7 (4.5) 18.1 (4.5) 16.9 (4.2) 24.2 (3.9) 19.8 (4.4) <.0001
1 The n is unweighted. The sample size may vary for some variables, because of missing values. Means and standard deviations (SD) and p-values for country-
differences tested with ANOVA are presented for normally distributed continuous variables. Medians and Interquartile ranges (IQR) and p-values for country-
differences tested with Kruskal-Wallis test are presented for skewed continuous variables. Percentages and p-values for country-differences tested with the
Chi-squared were presented for categorical variables.
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The prevalence rates for self-reported OA varied from
21.8% for hip OA, 34.1% for knee OA, and 33.8% for
hand OA. ACR criteria for clinical hip OA were satisfied
in 171 participants, and the prevalence of clinical hip
OA was 6.1%. The German participants had the lowest
prevalence of clinical hip OA and the Italian, the highest.
Of the total sample, 570 participants fulfilled the ACRclassification criteria for clinical knee OA, and the
prevalence of clinical knee OA was 20.2%. The highest
prevalence rate for clinical knee OA was in Italy and the
lowest in Germany. ACR criteria for clinical hand OA
were satisfied in 482 participants, and the prevalence of
clinical hand OA was 17.1%. In Italy the participants had
the highest prevalence rate of clinical hand OA and in
the Netherlands, the lowest. ACR criteria for any clinical
Table 3 Prevalence rate of self-reported and clinical OA and joint replacements by country (weighted)
All countries Germany Italy Netherlands Spain Sweden UK p-value
Self-reported OA (%)
Knee 34.1 28.4 44.2 26.2 45.0 34.9 22.0 <.0001
Hip 21.8 7.0 35.5 19.1 24.1 27.3 11.6 <.0001
Hand 33.8 28.8 44.2 29.4 38.0 42.3 13.1 <.0001
Any knee, hip or hand 52.8 45.6 68.8 44.3 56.8 60.2 35.8 <.0001
Anywhere in the body 58.8 51.7 79.4 48.9 61.3 65.7 39.2 <.0001
Clinical OA (%)
Knee 20.2 11.0 28.8 18.2 24.1 20.0 15.9 <.0001
Hip 6.1 0.8 13.8 6.7 4.4 5.0 4.7 <.0001
Hand 17.1 13.3 24.1 11.3 19.3 19.4 14.7 <.0001
Any knee, hip or hand 31.7 21.9 43.9 25.9 35.4 33.3 27.6 <.0001
Joint replacements (%)
Knee replacements 3.9 3.5 3.2 2.9 4.9 3.3 6.5 ns
Hip replacements 6.4 7.7 6.7 9.2 2.4 6.5 5.7 <.001
Hand/fingers replacements 0.1 0 0 0.4 0.1 0.1 0 ns
Any joint replacements 12.3 12.1 10.6 15.2 10.2 11.6 14.2 ns
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and the prevalence for any clinical knee, hip or hand OA
was 31.7%. Of those with any clinical knee, hip or hand
OA, 68.8% had OA at one site, 25.1% at two sites and
6.1% at all three sites.
Overall, 12.3% of the participants had a joint replace-
ment, with the Netherlands having the highest number
of any joint replacements (15.2%) and Spain the lowest
(10.2%). Most of these participants had either a hip
(6.4%) or knee replacement (3.9%). No significant differ-
ences were found between countries for knee replace-
ments. The Netherlands had the largest share of
participants with hip replacements (9.2%) and Spain the
smallest (2.4%).
Discussion
To our best knowledge, the EPOSA study is the first
population-based study using pre-harmonized data
across European countries on older community-dwelling
persons aged 65 to 85 years, where the ACR classifica-
tion criteria have been applied to determine the preva-
lence of knee, hip and hand OA. This study combines
data of existing cohort studies across six European coun-
tries varying in climate, socio-economic status, life style,
and health care policies.
The combined set of assessments of physical, cognitive,
psychological and social functioning, lifestyle behaviour,
physical environment, wellbeing and care utilisation, to-
gether with a clinical examination including anthropom-
etry, muscle strength, physical performance and OA exam
will provide an extensive new resource for future studies
on the personal and societal burden and its determinantsof osteoarthritis. The inclusion of a pain calendar will
allow the examination of variation in joint pain over time.
The EPOSA project focuses primarily on knee, hip and
hand OA. Because the project is population-based and
not a clinical study, it was necessary to limit the clinical
exam to the most common types of OA. Overall, the
prevalence of knee OA was the highest, followed by
hand OA, and hip OA, for both self-reported and clin-
ical OA. Cross-national differences are observed in
prevalence rates of both self-reported and clinical OA.
In Italy the prevalence rates for knee, hip, and hand clin-
ical OA were the highest, and in Germany the prevalence
rates for knee and hip clinical OA were the lowest. Radio-
graphs of the knee and hip in the UK will enable further
understanding of the association between radiological and
clinical OA and the study characteristics [37].
The differences in prevalence rates may be partly due
to national differences such as climate, health care, life-
style or environmental factors [2]. Still, the specificity of
the definition of OA is crucial for the prevalence rates.
In Germany, an index question was used to ascertain
whether participants had pain at each site (knee, hip or
hand), before the specific WOMAC/AUSCAN pain
questions were asked. This may have influenced the low
prevalence rate of clinical OA in Germany.
The use of the population-based approach rather than
a more limited clinical sample will allow generalisation
of our findings to comparable populations of older
adults. The project provides a unique opportunity to
study both persons with mild and severe OA, and those
seeking care and not seeking care. The study cohort is
representative of older adults living in the community.
van der Pas et al. BMC Musculoskeletal Disorders 2013, 14:138 Page 10 of 11
http://www.biomedcentral.com/1471-2474/14/138Evidence of a responder bias was apparent for some of
the six study cohorts. Such a response bias could impact
the disease outcome and should be taken into account
when using the EPOSA data [38].
The EPOSA study incorporates data from six
population-based cohort studies in Europe, enabling
cross-national comparison in OA prevalence rates and
correlates. A study with such a high number of individ-
uals using pre-harmonized data offers unique opportun-
ities for longitudinal investigations.
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